Search Results

MediciNova, Inc. announces that its Chief Business Officer, David H. Crean, Ph.D., will assume management of the Company’s investor engagement, corporate communications, and public relations activities.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the Standard Market of the Tokyo Stock Exchange, announced that MediciNova conducted two poster presentations at the 92nd European Atherosclerosis Society 2024 Congress held online May 26-29, 2024.

MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the prevention of metastasis of eye cancer.

MediciNova, Inc. announced that MediciNova’s collaborator, Gilbert Youssef, M.D. at Harvard Medical School, Attending Physician, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, presented new data and results of a Phase 1b/2a Clinical Trial of MN-166 in Glioblastoma at the American Society of Clinical Oncology Annual meeting 2024 held May 31- June 4th in Chicago, IL.

MediciNova, Inc. announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166.

MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the prevention of metastasis in various cancers including pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, and ovarian cancer.

MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the treatment of chlorine-induced acute respiratory distress syndrome.

MediciNova, Inc. today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.

MediciNova, Inc. announced that MediciNova’s collaborator, Perenlei Enkhbaatar, MD, PhD, FAHA, Professor, Department of Anesthesiology, Director, Translational Intensive Care Unit, Charles Robert Allen Professor in Anesthesiology, University of Texas Medical Branch, presented new data and results of a nonclinical study evaluating MN-166 in a CIALI model at the SOT 63rd Annual Meeting and ToxExpo in Salt Lake City, Utah.